Results from the phase 1 RaDDtrial (NCT03610061) radiotherapy added to immunotherapy enhanced responses, demonstrated manageable safety, and was informed by T-cell dysregulation in patients with B-cell lymphomas. 1
The objective response rate…
T-Cell Dysregulation Could Shape Radiotherapy in B-Cell Lymphoma | Targeted Oncology
